Naproxen
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Naproxen: Brachydactyly-syndactyly syndrome
One-Sentence Summary
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) originally used for conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, bursitis, tendinitis and migraine. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 0.9935 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Naproxen is generally known as a non-selective COX inhibitor with anti-inflammatory and analgesic effects, and its efficacy in inflammatory joint and pain conditions is established.
Brachydactyly-syndactyly syndrome, however, is a congenital skeletal malformation with a developmental and genetic basis. Blocking prostaglandin synthesis is not expected to correct a structural limb patterning defect, so no mechanistic link is supported by the available data. The high score (0.9935) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The other three top-ranked predictions show the same pattern. All are rare congenital developmental syndromes, with no trials or literature:
- Colobomatous microphthalmia-rhizomelic dysplasia syndrome (0.9922)
- Acromesomelic dysplasia, Hunter-Thompson type (0.9917)
- Brachyolmia-amelogenesis imperfecta syndrome (0.9906)
At most, naproxen might relieve joint pain symptomatically in some of these patients, which is not a repurposing claim.
India Market Information
Naproxen has 20 valid single-ingredient registrations and no cancelled ones. The data compiled for this report do not include approved indication text for these products. Main authorizations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 244550 | Xenap 250 Tablet | Strip of 10 tablets | Not stated |
| 153983 | Nalyxan 250mg Tablet | Strip of 10 tablets | Not stated |
| 152315 | Napsea Tablet | Strip of 10 tablets | Not stated |
| 151203 | Naprosyn 125mg Suspension | Bottle of 60 ml suspension | Not stated |
| 150316 | Naxdom 250 Tablet | Strip of 15 tablets | Not stated |
Available forms are oral tablets and an oral suspension. Several registrations are fixed-dose products, although the data classify all as single-ingredient (for example, the “D” and “250mg/10mg” products).
Safety Considerations
- Contraindications / disease associations (knowledge graph, not label text): Naproxen is linked to the following conditions, grouped by area:
- Cardiovascular: hypertension, congestive heart failure, coronary artery disease, coronary atherosclerosis, myocardial infarction, coronary thrombosis, stroke, cerebrovascular disorder, cerebral infarction
- Liver and kidney: liver failure, liver disease, kidney disease, gallbladder disease
- Metabolic: diabetes mellitus, diabetic ketoacidosis, obesity, osteoporosis
- Blood: blood coagulation disease, anaemia, hemoglobinopathy
- Other: epilepsy, benign prostatic hyperplasia, substance abuse/dependence
- Drug Interactions: 309 interactions are recorded. The 20 listed in the data are all Moderate-level and include:
- Acid-lowering agents: famotidine, ranitidine, cimetidine, rabeprazole, dexlansoprazole
- Corticosteroids: hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide
- Other: acetylsalicylic acid, metformin, chlorpropamide, mesalazine, balsalazide, aprepitant, potassium citrate, potassium bicarbonate
Please refer to the package insert for warnings and formal contraindications, as label-based data were not available.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (L5), with no clinical trials or publications, and there is no plausible mechanistic link between COX inhibition and correcting a congenital skeletal malformation. The cardiovascular, renal, hepatic and gastrointestinal risk profile of naproxen further weakens any case for use in this setting.
To proceed, the following is needed:
- Mechanism of action data (MOA) and a documented rationale linking it to the disease’s biology
- Any preclinical, case-based or clinical evidence in this or related syndromes
- Package insert warnings and contraindications for the India products
- Route and formulation compatibility assessment
- Confirmation of whether any benefit would be only symptomatic (joint pain) rather than disease-modifying
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.